Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 3, 2013, Pages 683-697

  Podolski Renić, Ana ^a   Jadranin, Milka ^b   Stanković, Tijana ^a   Banković, Jasna ^a   Stojković, Sonja ^a   Chiourea, Maria ^c   Aljančić, Ivana ^b   Vajs, Vlatka ^b   Tešević, Vele ^d   Ruždijić, Sabera ^a   Gagos, Sarantis ^c   Tanić, Nikola ^a   Pešić, Milica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Anticancer agents; Cytogenetics; Loss of heterozygosity; Multi drug resistance; P glycoprotein

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; EUPHODENDROPHANE H; EUPHODENDROPHANE S; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TIPIFARNIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE PHASE; CHEMOSENSITIVITY; CHROMOSOME 6Q; CHROMOSOME ANALYSIS; CHROMOSOME STRUCTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; GENE INACTIVATION; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MDR1 GENE; MOLECULAR MODEL; MULTIDRUG RESISTANCE; PHENOTYPIC VARIATION; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; TUMOR GENE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOGENETIC ANALYSIS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; LUNG NEOPLASMS; OXADIAZOLES; P-GLYCOPROTEIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883488322     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2247-1     Document Type: Article

References (44)

1. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
2. Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237
3. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275-292
4. Ferreira CG, Tolis C, Giaccone G (1999) p53 and chemosensitivity. Ann Oncol 10(9):1011-1021
5. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3 K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249-279
6. Priulla M, Calastretti A, Bruno P, Azzariti A, Paradiso A, Canti G, Nicolin A (2007) Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 67:782-789
7. Lee AJ, Swanton C (2011) Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics. Biochem Pharmacol 83:1013-1020
8. McClelland SE, Burrell RA, Swanton C (2009) Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 8:3262-3266
9. Ben-Yehoshua JL, Beider K, Shimoni A, Ostrovsky O, Samookh M, Peled A, Nagler A (2012) Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death. PLoS ONE 7:e33856
10. Duesberg P, Stindl R, Hehlmann R (2001) Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad of Sci USA 98:11283-11288
11. Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q et al (2009) Chromosomal instability determines taxane response. Proc Natl Acad Sci USA 106:8671-8676
12. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S et al (2005) Cancer cell adaptation to chemotherapy. BMC Cancer 18(5):78
13. Brózik A, Hegedüs C, Erdei Z, Hegedus T, Özvegy-Laczka C, Szakács G, Sarkadi B (2011) Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 7:623-642
14. Pešić M, Marković JZ, Janković D, Kanazir S, Marković ID, Rakić L, Ruždijić S (2006) Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 18:66-73
15. Podolski-Renić A, Andelković T, Banković J, Tanić N, Ruždijić S, Pešić M (2011) The Role of paclitaxel in the development and treatment of multi-drug resistant cancer cell lines. Biomed Pharmacother 65:345-353
16. Jadranin M, Pešić M, Aljančić IS, Milosavljević SM, Todorović NM, Podolski-Renić A, Banković J, Tanić N, Marković I, Vajs VE, Tešević VV (2013) Jatrophane diterpenoids from the latex of Euphorbia dendroides and their anti-P-glycoprotein activity in human multi-drug resistant cancer cell lines. Phytochemistry 86:208-217
17. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ (1999) Clonal expansion, and loss of heterozygosity at chromosomes 9p, and 17p in premalignant esophageal (Barrett's) tissue. J Nat Cancer Inst 91:2087-2095
18. Reid BJ, Prevo LJ, Galipeau PC et al (2001) Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96:2839-2848
19. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM (1998) Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16:1743-1748
20. Hahn M, Wieland I, Koufaki ON et al (1999) Genetic alterations of the tumor suppressor gene PTEN/MMAC1 in human brain metastases. Clin Cancer Res 5:2431-2437
21. Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 114:143-149
22. Hüebner C, Petermann I, Browning BL, Shelling AN, Ferguson LR (2007) Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol Biomarkers Prev 16:1185-1192
23. Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH (2003) MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 73:1282-1292
24. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
25. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
26. Mancini M, Vegna ML, Castoldi GL, Mecucci C, Spirito F, Elia L, Tafuri A, Annino L, Pane F, Rege-Cambrin G, Gottardi M, Leoni P, Gallo E, Camera A, Luciano L, Specchia G, Torelli G, Sborgia M, Gabbas A, Tedeschi A, Della Starza I, Cascavilla N, Di Raimondo F, Mandelli F, Foà R (2002) Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia. Leukemia 16:2055-2061
27. Tegze B, Szállási Z, Haltrich I, Pénzvá ltó Z, Tóth Z, Likó I, Gyorffy B (2012) Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS ONE 7:e30804
28. Erenpreisa J, Cragg MS (2010) MOS, aneuploidy and the ploidy cycle of cancer cells. Oncogene 29:5447-5451
29. Sabisz M, Skladanowski A (2009) Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models. Cell Cycle 8:3208-3217
30. Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, Ruzdijic S (2008) Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol Ther 7:1024-1032
31. Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z, Cecchetto M, Parissenti AM (2008) Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer 8:318
32. Glynn SA, Gammell P, Heenan M, O'Connor R, Liang Y, Keenan J, Clynes M (2004) A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br J Cancer 91:1800-1807
33. Aljančić IS, Pešić M, Milosavljević SM, Todorović NM, Jadranin M, Milosavljević G, Povrenović D, Banković J, Marković ID, Ruždijić S, Vajs VE, Tešević VV (2011) Isolation and biological evaluation of jatrophane diterpenoids from Euphorbia dendroides. J Nat Prod 74:1613-1620
34. Burris HA 3rd (2013) Overcoming acquired resistance to anticancer therapy: focus on the PI3 K/AKT/mTOR pathway. Cancer Chemother Pharmacol 71:829-842
35. Britten CD (2013) PI3 K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol 71:1395-1409
36. MacKeigan JP, Collins TS, Ting JP (2000) MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 275:38953-38956
37. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Cancer Res 62:1087-1092
38. Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T, Eckhardt SG (2007) The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 21:739-746
39. Corea G, Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Appendino G, Ballero M, Simon PN, Dumontet C, Di Pietro A (2003) Jatrophane diterpenes as P-glycoprotein inhibitors. First insights of structure-activity relationships and discovery of a new, powerful lead. J Med Chem 46:3395-3402
40. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528
41. Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794:860-871
42. Miglietta A, Gabriel L, Appendino G, Bocca C (2003) Biological properties of jatrophane polyesters, new microtubule-interacting agents. Cancer Chemother Pharmacol 51:67-74
43. Pešić M, Banković J, Aljančić IS, Todorović NM, Jadranin M, Vajs VE, Tešević VV, Vučković I, Momčilović M, Marković ID, Tanić N, Ruždijić S (2011) New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides. Food Chem Toxicol 49:3165-3173
44. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI et al (2011) Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA 108:18708-18713